Correlation Between In Vivo Antipyrine Metabolite Formation and Theophylline Metabolism in Rats
- 1 January 1986
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 03 (3) , 156-161
- https://doi.org/10.1023/a:1016361907787
Abstract
Two model substrates for oxidative hepatic enzyme activity, viz. antipyrine (A) and theophylline (T), were given simultaneously to rats by iv administration. Blood concentrations of A and T were measured by a high-performance liquid chromatographic (HPLC) method. Urinary excretions of A, T, and the major metabolites arising from A—4-hydroxyantipyrine (OHA), norantipyrine (NORA), 3-hydroxymethylantipyrine (HMA), and 4,4′-dihydroxyantipyrine (DOHA)—and from T—1-methyluric acid (1-MU) and 1,3-dimethyluric acid (1,3-DMU)—were also determined by HPLC. It was found that the pharmacokinetic parameters obtained after the simultaneous administration of A and T at relatively low dose levels (A, 5.0 mg; and T, 1.3 mg) were not different from those obtained after the separate administration of A or T at the same dose level. In order to investigate whether the metabolic pathways of A and T are mediated by the same or closely related forms of the cytochrome P-450 system, metabolic clearances of A (CLA,M) and T (CLT,M) and the clearances for production of their various metabolites, obtained in untreated rats and in rats pretreated with 3-methylcholanthrene (MC) or with MC followed by 9-hydroxyellipticine (E), were correlated. These two compounds are a selective cytochrome P-448 inducer and inhibitor, respectively. Strong correlations were found between CLT,M and the clearances for production of OHA, NORA, and DOHA but not HMA. The best correlation, however, was observed between CLT,M and CLOHA, not only when all data points were taken into account (r = 0.99), but also in separate pretreatment groups (r ranging from 0.87 to 0.92). Moreover, the slopes of these correlation lines varied only slightly among groups, while the intercepts were not significantly different from zero. In the separate pretreatment groups, the correlation coefficients for the correlations between CLT,M and the clearance for production of the other metabolites of A were considerably lower, while the slopes of the correlation lines varied substantially. Clearances for production of the metabolites of T were strongly correlated with each other (r = 0.99) and with CLOHA (r = 0.95). It can be concluded that theophylline metabolism and formation of OHA are mediated by the same or very similar forms of cytochrome P-450, whereas formation of the other major metabolites of A is not or only partly. The study of the various pathways of metabolism after simultaneous administration of drugs is a powerful tool in the study of correlations in drug metabolism in vivo.This publication has 21 references indexed in Scilit:
- Dose-dependent elimination of theophylline in ratsXenobiotica, 1985
- Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity.British Journal of Clinical Pharmacology, 1983
- Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in ratsXenobiotica, 1983
- Influence of 9-hydroxyellipticine and 3-methylcholanthrene treatment on antipyrine metabolite formation in rats in vivoXenobiotica, 1983
- Interindividual Variations in Drug DispositionClinical Pharmacokinetics, 1983
- Dose-dependent kinetics for theophylline: Observations among ambulatory asthmatic childrenThe Journal of Pediatrics, 1980
- Antipyrine metabolism in the rat by three hepatic monooxygenasesLife Sciences, 1980
- Effects of phenobarbital and 3-methylcholanthrene pretreatment on the plasma half-life and urinary excretion profile of theophylline and its metabolites in ratsBiochemical Pharmacology, 1979
- Studies on the Different Metabolic Pathways of Antipyrine in Rats: Influence of Phenobarbital and 3-Methylcholanthrene TreatmentXenobiotica, 1979
- Benzo(a)pyrene Metabolism and Plasma Elimination Rates of Phenacetin, Acetanilide and Theophylline in ManPharmacology, 1978